



Figure S6. MPNST xenografts and effects with BCI. **A**, Representative images of hematoxylin and eosin (H&E) and **B**, immunohistochemical staining for human nucleoli antigen (HNA) in the PDX xenograft MPNST model. Scale bar is 100 μ m. **C**, Representative images and quantification of trichrome staining with BCI 10 mg/kg, i.p. by oral gavage, or vehicle once daily, 5x/wk for 27 days in the TY xenograft and 21 days in the PDX xenograft model. Scale bar is 100 μ m. **D**, Immunoblot of total levels ERK, JNK and c-jun and **E**, of cyclin D1, TP53, p-RB and p-ATM from the TY model with BCI 10 mg/kg, i.p. by oral gavage, or vehicle once daily, 5x/wk for 27 days sacrificed 2 hours after the last dose. **F**, Immunoblot analysis of MAPK signaling markers in PDX MPNST tumors. Mice were dosed with BCI 25 mg/kg, i.p. once daily, 5x/wk for 21 days or

vehicle and were sacrificed 2 or 6 hours after the last dose. **G**, Immunoblot of total levels ERK, JNK and c-jun and **H**, of cyclin D1, TP53, p-RB and p-ATM from the PDX model with BCI 10 mg/kg, i.p. by oral gavage, or vehicle once daily, 5x/wk for 12 days sacrificed 2 hours after the last dose.